Victor Villegas, MD
Ophthalmology · San Juan, PRNPI 1174771653
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,751 of the $5,048 with a category attached, or 74.3%. 16 manufacturers reported payments, led by Alimera Sciences, Inc. at 31.2% of the total. Reporting peaked in 2022 at $1,523 and has fallen 55.3% since, to $680 in 2025. Among ophthalmology clinicians in PR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 105 payments — averaging $48.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alimera Sciences, Inc.$2K
- AbbVie$1K
- Regeneron Healthcare Solutions, Inc.$426
- Bausch & Lomb Americas Inc.$358
- Novartis$346
- Alcon Puerto Rico Inc$321
- plus $908 from 10 others
What the payments were for
- Speaking & faculty fees$1,29726%
- Food & beverage$3,75174%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alimera Sciences, Inc. | 4 | $1,575 |
| AbbVie(2 entities) | 45 | $1,113 |
| Regeneron Healthcare Solutions, Inc. | 6 | $426 |
| Bausch & Lomb Americas Inc. | 16 | $358 |
| Novartis | 9 | $346 |
| Alcon Puerto Rico Inc | 8 | $321 |
| Apellis Pharmaceuticals, Inc. | 3 | $267 |
| Genentech USA, Inc. | 5 | $214 |
| Samsara Vision | 1 | $139 |
| Dutch Ophthalmic, USA | 1 | $106 |
| Alcon | 1 | $52 |
| Genentech, Inc. | 2 | $48 |
| Mallinckrodt Hospital Products Inc. | 1 | $28 |
| Amgen | 1 | $22 |
| ANI Pharmaceuticals, Inc. | 1 | $18 |
| Eyepoint US, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Iluvien$1,458
- EYLEA$347
- Implantable Miniature Telescope$139
- VABYSMO$127
- Syfovre$125
- NGENUITY$125
- EVA Ophthalmic Surgical System$106
- BEOVU$104
How this compares
$5,048 in reported general payments places this provider in the 90th percentile of 214 ophthalmology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 371 | $100,123 |
| VabysmoFaricimab-Svoa | 26 | $76,272 |
| Fluorometholone | 793 | $56,256 |
| EyleaAflibercept | 18 | $47,804 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,106 | $37,377 |
| Prednisolone Acetate | 648 | $29,494 |
| Ketorolac Tromethamine | 885 | $25,962 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 125 | $19,548 |
| Alphagan PBrimonidine Tartrate | 78 | $17,449 |
| Latanoprost | 1,280 | $16,697 |
| Brimonidine Tartrate | 471 | $15,766 |
| RestasisCyclosporine | 22 | $11,370 |
| CombiganBrimonidine Tartrate/Timolol | 46 | $10,574 |
| Acetazolamide | 78 | $7,853 |
| IlevroNepafenac | 20 | $7,581 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Alphagan P, Restasis, Combigan | $1,113 | $139,517517 claims |
| Genentech USA, Inc.Vabysmo | $214 | $76,27226 claims |
| Regeneron Healthcare Solutions, Inc.Eylea | $426 | $47,80418 claims |
| NovartisIlevro | $346 | $7,58120 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $358 | $5,69121 claims |
| AlconSimbrinza | $52 | $5,47126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 214 ophthalmology providers in Puerto Rico.
Other ophthalmology in San Juan
- Maria Berrocal FernandezSan Juan$547K
- Jose MontesSan Juan$396K
- Juan Nevarez MarreroSan Juan$19K
- Natalio Izquierdo EncarnacionSan Juan$16K
- Ian PiovanettiSan Juan$11K
- Jaime Bravo CastroSan Juan$8K
- Ernesto CollazoSan Juan$7K
- Gustavo HernandezSan Juan$5K
- Gabriela Trabal YulfoSan Juan$4K
- Esteban Vazquez-ValenciaSan Juan$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.